Recent Updates
Recently added Catalysts

Polyrizon Ltd.

PLRZFDA catalysts, PDUFA dates & pipeline intelligence
$10.7
▼ -0.35 · -3.17%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full PLRZ financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $2.8852W HIGH $18.20
Volume
4.34 K
Value Traded
46.69 K
Short % Float
2.56%
Days to Cover
4.0
-2.1%Week
+10.48%1 Month
+3.28%3 Month
-23.46%6 Month
-99.38%5 Year
-99.38%All Time

Cash Data

Unlock PLRZ cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
25.99 M
EPS (TTM)
-2.70
P/E Ratio
-
Ent. Value
14.92 M
Total Shares
2.43 M
Float Shares
2.36 M
Insiders
0.59%
Institutions
9.24%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every PLRZ catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

PLRZ Catalyst Timeline

Dated clinical, regulatory and corporate events for Polyrizon Ltd.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Polyrizon Ltd.

4Total events
2Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage

Upcoming catalysts 2

TBD
T2Trial Initiation
Subscribe to view catalyst details
NASARIX
TBD
T3Enrollment Update
Subscribe to view catalyst details
NASARIX

Event history 2

▲Preclinical PoCNASARIXPreclinical
Successful completion of NASARIX biocompatibility evaluation program
seasonal allergic rhinitissource ↗
▲Trial InitiationNASARIXTrial
Central IRB approval received for first human clinical trial of NASARIX
seasonal allergic rhinitissource ↗
Unlock the full PLRZ catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How PLRZ actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all PLRZ historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

No drug pipeline

Polyrizon Ltd. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.

Clinical Trial Results

Readouts, endpoints and source filings for every PLRZ program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
naloxone 2026-02-26significantly higher deposition in the nasal vestibule region compared to the commercial reference productRead MorePolyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference ProductRead More
Scroll for more · summaries link to the source press release
Unlock every PLRZ trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock PLRZ insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Adler OzDirectorSell -3,292 19,850 held$12.05 03/31/2026
Unlock the full PLRZ insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in PLRZ for Q3 2026.
Unlock every fund holding PLRZ
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in PLRZ
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see PLRZ ownership
Insider and institutional ownership, quarter by quarter.

PLRZ Short Interest

Shares sold short, counted twice a month.

2.56%
Short % of Float
of tradable shares sold short
60.5K
Shares Sold Short
-11.5% vs prior count
4.0 Moderate
Days to Cover
trading days of normal volume to buy every short share back
15.1K
Avg Daily Volume
the average used for days to cover
Unlock PLRZ short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock PLRZ option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live PLRZ option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock PLRZ options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How PLRZ ranks across every disease it competes in

Competitive Position is a premium feature
See how PLRZ ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

PLRZ News

PLRZ
Nov 9, 2026
PLRZGeneral

POLYRIZON ADOPTS LIMITED DURATION SHAREHOLDER RIGHTS PLAN

Polyrizon Ltd. has adopted a limited duration shareholder rights plan to protect its shareholders amid ongoing trading price dislocation. The plan, effective immediately, aims to ensure that any potential acquirer negotiates directly with the Board before attempting to gain control. It will be submitted for ratification at the next shareholder meeting.

Read more →
PLRZ
Oct 27, 2026
PLRZPhases

Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker

Polyrizon has completed the enrollment of 120 participants in its U.S. clinical study of NASARIX, an investigational nasal hydrogel designed to protect against airborne allergens. The study aims to evaluate NASARIX's effectiveness in managing allergic rhinitis symptoms. The company plans to proceed with data analysis following the treatment and follow-up periods.

Read more →
PLRZ
Oct 5, 2026
PLRZFDA Updates

Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform

Polyrizon Ltd. has filed a new U.S. divisional patent application to enhance its intellectual property related to its mucoadhesive technology for nasal drug delivery. This application is part of a broader patent family aimed at supporting various therapeutic applications through mucosal tissues. The CEO highlighted the potential of the technology beyond barrier applications, focusing on therapeutic delivery.

Read more →
PLRZ
Sep 22, 2026
PLRZPhases

Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker

Polyrizon has enrolled its first patient in a U.S. clinical study for NASARIX (PL-14), an investigational allergy blocker for seasonal allergic rhinitis. This marks a pivotal transition for the company into clinical development. The study aims to evaluate the efficacy, safety, and tolerability of NASARIX compared to a saline nasal spray in 120 patients.

Read more →
PLRZ
Sep 4, 2026
PLRZGeneral
▼ -9.9%on this news

Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement

Polyrizon Ltd. has closed a $4.0 million registered direct offering and private placement, issuing shares and warrants to a single institutional investor. The funds raised will be utilized for general corporate purposes and working capital. The transactions included the issuance of Ordinary Shares and pre-funded warrants, with a combined offering price of $12.00 per unit.

Read more →
PLRZ
Sep 3, 2026
PLRZGeneral

Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement

Polyrizon Ltd. has announced a $4.0 million registered direct offering and private placement with a single institutional investor. The offering includes the sale of Ordinary Shares and pre-funded warrants, expected to close on September 4, 2026. The proceeds will be used for corporate purposes and working capital, enhancing the company's innovative hydrogel technology.

Read more →
PLRZ
Sep 2, 2026
PLRZPhases
▼ -12.9%on this newsshared move

Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study

Polyrizon Ltd. has successfully completed contracting with all five U.S. clinical sites for its NASARIX™ Allergy Blocker study. This first-in-human trial aims to assess the efficacy, safety, and tolerability of NASARIX™ in patients with seasonal allergic rhinitis. The study will enroll up to 120 patients and is set to begin patient pre-screening and enrollment activities.

Read more →
PLRZ
Aug 20, 2026
PLRZPhases
▼ -8.8%on this news

Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment

Polyrizon Ltd. has completed contracting with all five clinical sites for its NASARIX™ study, which aims to enroll 120 patients with seasonal allergic rhinitis. The study will evaluate the efficacy, safety, and tolerability of NASARIX™ compared to a saline control. With patient pre-screening underway, enrollment is timed to coincide with relevant allergy seasons.

Read more →
PLRZ
Jul 2, 2026
PLRZFDA Updates
▲ +8.8%on this news· ran to +20% by day 1

Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial

Polyrizon Ltd. announced successful results from its biocompatibility evaluation program for NASARIXTM, a drug-free nasal spray aimed at reducing exposure to allergens. The program met all biological safety tests and was conducted in accordance with international standards. This milestone supports the product's advancement towards clinical trials and potential commercialization.

Read more →
PLRZ
Jun 29, 2026
PLRZPhases
▲ +11.1%on this newsshared move

Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial

Polyrizon Ltd. has received central IRB approval for its first human clinical trial of NASARIX, a nasal spray designed to block airborne allergens. The approval, granted by the BRANY Institutional Review Board, confirms that the study protocol meets ethical and participant protection standards. The trial will evaluate NASARIX's efficacy compared to a saline spray in patients with seasonal allergic rhinitis.

Read more →
PLRZ
Jun 17, 2026
PLRZFDA Updates
▲ +15.5%on this news

Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform

Polyrizon Ltd. has announced the publication of a U.S. patent application for its Trap & Target™ mucoadhesive polymer technology aimed at enhancing nasal drug delivery. This platform is designed to improve drug absorption and retention through the nasal mucosa, potentially benefiting various therapeutic applications. The technology combines biocompatible polymers to create effective formulations for both localized and systemic drug delivery.

Read more →
PLRZ
Jun 15, 2026
PLRZPhases

Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway

Polyrizon Ltd. has partnered with a prominent European medical center to conduct a human study on its NASARIX™ allergy blocker. This study will assess the nasal residence time of the formulation, which is crucial for understanding its protective barrier function. The findings are expected to support the company's regulatory strategy, including submissions to the FDA.

Read more →
PLRZ
Jun 10, 2026
PLRZFDA Updates

Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology

Polyrizon Ltd. announced the publication of its European patent application for its innovative mucoadhesive polymer technology aimed at enhancing nasal drug delivery. This technology seeks to improve drug absorption and retention time in the nasal cavity, addressing key challenges in the field. The patent publication is a significant milestone for Polyrizon as it strengthens its intellectual property portfolio and supports future pharmaceutical collaborations.

Read more →
PLRZ
Jun 8, 2026
PLRZPhases

Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial

Polyrizon Ltd. has announced the addition of two new U.S. clinical sites for its NASARIX™ trial, bringing the total to three. These sites are crucial for the planned multi-center study evaluating the safety and efficacy of the NASARIX™ Allergy Blocker for seasonal allergic rhinitis. The company is optimistic about efficient patient recruitment and timely trial execution.

Read more →
PLRZ
May 13, 2026
PLRZPhases

Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial

Polyrizon Ltd. has signed a Clinical Trial Agreement with a U.S. clinical site, marking a significant step towards human clinical trials for its NASARIX™ Allergy Blocker. The study will assess the safety, tolerability, and efficacy of the nasal spray in patients suffering from seasonal allergic rhinitis. This multi-center trial is expected to adhere to international Good Clinical Practice standards.

Read more →
PLRZ
May 4, 2026
PLRZFDA Updates

Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform

Polyrizon Ltd. has announced the submission of amended claims for its U.S. patent application, expanding the scope of its intranasal drug delivery platform. The new claims include drug delivery systems and methods aimed at improving medication effectiveness. This move is part of Polyrizon's strategy to enhance its global intellectual property portfolio and potentially improve treatment outcomes across various therapeutic areas.

Read more →
PLRZ
Apr 27, 2026
PLRZGeneral
▲ +6.9%on this newsshared move

Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform

Polyrizon Ltd. has filed a divisional patent application with the European Patent Office for its innovative Trap & Target (T&T) intranasal drug delivery platform. This technology aims to enhance the bioavailability of medications and address challenges in drug delivery. The filing reinforces Polyrizon's commitment to protecting its intellectual property and advancing healthcare solutions.

Read more →
PLRZ
Apr 8, 2026
PLRZGeneral

Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements

Polyrizon Ltd. has successfully closed a $3.5 million registered direct offering and private placement with a single institutional investor. The offering included Ordinary Shares and pre-funded warrants, with proceeds aimed at supporting general corporate purposes. The company anticipates having over 2 million Ordinary Shares outstanding following the offering.

Read more →
PLRZ
Apr 7, 2026
PLRZGeneral
▼ -9.9%on this newsshared move

Polyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private Placement

Polyrizon Ltd. has announced a $3.5 million registered direct offering and private placement with a single institutional investor. The transactions involve the sale of Ordinary Shares and pre-funded warrants, with expected proceeds to be used for corporate purposes. The offering is set to close around April 8, 2026, pending customary conditions.

Read more →
PLRZ
Mar 26, 2026
PLRZGeneral

Polyrizon Provides 2025 and Recent Highlights

Polyrizon Ltd. has reported significant advancements in its intranasal protective solutions, including successful FDA meetings and preclinical results. The company is preparing for potential human clinical trials and has established collaborations to support its clinical development. With a strong cash position and a debt-free balance sheet, Polyrizon is well-positioned for future growth.

Read more →

About Polyrizon Ltd.

BIOPHARMAWATCH ELITE
Trade the next PLRZ catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime